JPWO2022068878A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022068878A5 JPWO2022068878A5 JP2023520181A JP2023520181A JPWO2022068878A5 JP WO2022068878 A5 JPWO2022068878 A5 JP WO2022068878A5 JP 2023520181 A JP2023520181 A JP 2023520181A JP 2023520181 A JP2023520181 A JP 2023520181A JP WO2022068878 A5 JPWO2022068878 A5 JP WO2022068878A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ring
- independently
- membered saturated
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011061580 | 2020-09-30 | ||
| CN202011061580.7 | 2020-09-30 | ||
| PCT/CN2021/121721 WO2022068878A1 (zh) | 2020-09-30 | 2021-09-29 | 一种抗肿瘤化合物及其制备方法和应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023551355A JP2023551355A (ja) | 2023-12-08 |
| JP2023551355A5 JP2023551355A5 (https=) | 2024-10-08 |
| JPWO2022068878A5 true JPWO2022068878A5 (https=) | 2024-10-08 |
Family
ID=80951198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520181A Pending JP2023551355A (ja) | 2020-09-30 | 2021-09-29 | 抗腫瘍化合物並びにその調製方法及び使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US11685742B2 (https=) |
| EP (2) | EP4223318A4 (https=) |
| JP (1) | JP2023551355A (https=) |
| KR (1) | KR20230079085A (https=) |
| CN (4) | CN116239601B (https=) |
| AU (1) | AU2021354823A1 (https=) |
| CA (1) | CA3195515A1 (https=) |
| FI (1) | FI4516357T3 (https=) |
| IL (1) | IL301793A (https=) |
| MX (1) | MX2023003778A (https=) |
| TW (1) | TW202214230A (https=) |
| WO (1) | WO2022068878A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023003778A (es) * | 2020-09-30 | 2023-04-26 | Duality Biologics Suzhou Co Ltd | Compuesto antitumoral, metodo de preparacion y uso del mismo. |
| BR112023023276A2 (pt) | 2021-05-07 | 2024-01-30 | Alx Oncology Inc | Derivados de exatecan e conjugados anticorpo-fármaco destes |
| CN115557962A (zh) * | 2021-07-02 | 2023-01-03 | 石药集团巨石生物制药有限公司 | 新型喜树碱类化合物及其制备方法和应用 |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CN115850291B (zh) * | 2021-09-24 | 2024-11-15 | 石药集团巨石生物制药有限公司 | 喜树碱衍生物及其用途 |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| WO2023138635A1 (zh) * | 2022-01-18 | 2023-07-27 | 甘李药业股份有限公司 | 一种依喜替康衍生物-抗体偶联物及其医药用途 |
| AU2023213783A1 (en) * | 2022-01-28 | 2024-08-15 | Duality Biologics (Suzhou) Co., Ltd. | Her3 antibody-drug conjugate and use thereof |
| EP4489790A1 (en) * | 2022-03-10 | 2025-01-15 | Vivasor, Inc. | Antibody-drug conjugates and uses thereof |
| WO2023174401A1 (zh) * | 2022-03-18 | 2023-09-21 | 映恩生物制药（苏州）有限公司 | Gpc3抗体药物偶联物及其用途 |
| CN118696048A (zh) * | 2022-05-09 | 2024-09-24 | 同宜医药（苏州）有限公司 | 一种喜树碱衍生物，基于其的抗体-药物偶联物和药物组合物，及其应用 |
| EP4524140A1 (en) * | 2022-05-13 | 2025-03-19 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor and use thereof |
| JP2025523382A (ja) | 2022-06-07 | 2025-07-23 | デュアリティ― バイオロジックス（スージョウ）シーオー．エルティーディー． | 抗ｂ７ｈ３抗体－薬物複合体及びその使用 |
| KR20250075560A (ko) | 2022-07-15 | 2025-05-28 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 항-trop2 항체 및 이의 접합체 |
| EP4562051A1 (en) * | 2022-07-26 | 2025-06-04 | Immunome, Inc. | Immunoconjugates and methods |
| CN117024438A (zh) * | 2022-07-29 | 2023-11-10 | 杭州爱科瑞思生物医药有限公司 | 依沙替康衍生物及其应用 |
| JP2025511436A (ja) * | 2022-09-02 | 2025-04-16 | メルク・シャープ・アンド・ドーム・エルエルシー | エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用 |
| EP4594327A1 (en) * | 2022-09-30 | 2025-08-06 | BeiGene Switzerland GmbH | Ligand-drug conjugate of exatecan analogue, and medical use thereof |
| PE20252282A1 (es) * | 2022-10-09 | 2025-09-18 | Lanova Medicines Ltd | Compuestos, composiciones y metodos |
| CN120417935A (zh) | 2022-10-25 | 2025-08-01 | 默沙东有限责任公司 | 依喜替康衍生的adc接头-载荷及其药物组合物和用途 |
| IL320634A (en) * | 2022-11-04 | 2025-07-01 | Alx Oncology Inc | EXATECAN derivatives and antibody-drug conjugates |
| CN119855820A (zh) * | 2022-12-16 | 2025-04-18 | 上海齐鲁制药研究中心有限公司 | 喜树碱类化合物及其制备方法和用途 |
| TW202430224A (zh) * | 2022-12-27 | 2024-08-01 | 大陸商映恩生物製藥（蘇州）有限公司 | 抗b7h3和pd-l1的雙特異性抗體藥物偶聯物及其製備方法和用途 |
| IL321193A (en) * | 2022-12-28 | 2025-07-01 | Adcendo Aps | Antibody-drug conjugates targeting UPARAP including extacan derivatives |
| CN116712561A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | 含n-亚甲基酰胺连接子的抗体-药物偶联物 |
| CN118684724A (zh) * | 2023-03-22 | 2024-09-24 | 映恩生物制药（苏州）有限公司 | 连接子及其在配体药物偶联物中的应用 |
| EP4696332A1 (en) | 2023-04-10 | 2026-02-18 | Daiichi Sankyo Company, Limited | Combination of anti-b7-h3 antibody-drug conjugate with atr inhibitor or atm inhibitor |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| WO2025031286A1 (zh) * | 2023-08-04 | 2025-02-13 | 映恩生物制药（苏州）有限公司 | 抗体药物偶联物的识别抗体及其应用 |
| WO2025054996A1 (en) | 2023-09-15 | 2025-03-20 | Duality Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugate |
| WO2025056748A1 (en) | 2023-09-15 | 2025-03-20 | Duality Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugate |
| WO2025166725A1 (en) | 2024-02-08 | 2025-08-14 | Duality Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugate |
| CN117417347A (zh) * | 2023-09-28 | 2024-01-19 | 杭州爱科瑞思生物医药有限公司 | 卤素取代的依沙替康的酰胺衍生物及其制备方法和应用 |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| WO2025162049A1 (zh) * | 2024-02-02 | 2025-08-07 | 长春金赛药业有限责任公司 | 卤代烯烃类喜树碱衍生物、药物组合物及其制备方法和应用 |
| WO2025238587A1 (en) | 2024-05-16 | 2025-11-20 | Daiichi Sankyo Company, Limited | Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor |
| WO2025247255A1 (zh) * | 2024-05-28 | 2025-12-04 | 映恩生物科技(上海)有限公司 | 一种抗dll3抗体、抗体药物偶联物及其应用 |
| WO2025247302A1 (zh) * | 2024-05-31 | 2025-12-04 | 杭州中美华东制药有限公司 | 一种喜树碱类化合物及其应用 |
| WO2025252101A1 (zh) * | 2024-06-05 | 2025-12-11 | 荣昌生物制药(烟台)股份有限公司 | 一种喜树碱类化合物及其用途 |
| WO2025257394A1 (en) * | 2024-06-14 | 2025-12-18 | BioNTech SE | Combination therapy for cancer treatment |
| WO2025256761A1 (en) * | 2024-06-14 | 2025-12-18 | BioNTech SE | Combination therapy for cancer treatment |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| HK1040052B (zh) * | 1998-05-22 | 2006-09-15 | 第一制药株式会社 | 药物复合物 |
| DK2907824T3 (en) | 2012-10-11 | 2018-07-23 | Daiichi Sankyo Co Ltd | ANTIBODY-drug conjugate |
| EP2910573B1 (en) * | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| SI3466976T1 (sl) * | 2014-01-31 | 2021-12-31 | Daiichi Sankyo Company, Limited | Anti-her2 konjugat protitelesa-zdravila |
| JP6612738B2 (ja) * | 2014-04-10 | 2019-11-27 | 第一三共株式会社 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| SG10201912173RA (en) * | 2016-10-07 | 2020-02-27 | Daiichi Sankyo Co Ltd | Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate |
| CN109106951A (zh) | 2017-08-18 | 2019-01-01 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| CN110016026B (zh) * | 2018-01-08 | 2022-11-25 | 上海凌济生物科技有限公司 | 一类具有抗肿瘤活性的嘧啶并吡啶酮类化合物、制备方法和用途 |
| WO2020063676A1 (zh) * | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
| CN112543771B (zh) * | 2018-09-30 | 2023-04-11 | 江苏豪森药业集团有限公司 | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 |
| CN113260384A (zh) | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | 用于靶向表达trop-2的肿瘤的抗体缀合物 |
| CN111689980A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种喜树碱药物及其抗体偶联物 |
| CN114341162B (zh) * | 2019-07-10 | 2025-10-17 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| CN112125915A (zh) | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
| KR20240038138A (ko) * | 2020-07-13 | 2024-03-22 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도 |
| MX2023003778A (es) * | 2020-09-30 | 2023-04-26 | Duality Biologics Suzhou Co Ltd | Compuesto antitumoral, metodo de preparacion y uso del mismo. |
| CN116472064A (zh) | 2020-10-12 | 2023-07-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
| US20250276078A1 (en) | 2020-10-12 | 2025-09-04 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Camptothecin Derivative And Ligand-drug Conjugate Thereof |
| CN114569739A (zh) | 2020-12-01 | 2022-06-03 | 正大天晴药业集团股份有限公司 | 抗体药物偶联物 |
| KR20250120438A (ko) | 2021-02-05 | 2025-08-08 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 캄프토테신 화합물, 그의 제조방법 및 그의 응용 |
| CN113816969B (zh) | 2021-04-30 | 2024-01-16 | 联宁（苏州）生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
| BR112023023276A2 (pt) | 2021-05-07 | 2024-01-30 | Alx Oncology Inc | Derivados de exatecan e conjugados anticorpo-fármaco destes |
-
2021
- 2021-09-29 MX MX2023003778A patent/MX2023003778A/es unknown
- 2021-09-29 KR KR1020237011470A patent/KR20230079085A/ko active Pending
- 2021-09-29 CN CN202310152789.1A patent/CN116239601B/zh active Active
- 2021-09-29 JP JP2023520181A patent/JP2023551355A/ja active Pending
- 2021-09-29 EP EP21874533.9A patent/EP4223318A4/en active Pending
- 2021-09-29 CN CN202211403184.7A patent/CN116199739B/zh active Active
- 2021-09-29 CN CN202211407530.9A patent/CN115925796B/zh active Active
- 2021-09-29 CA CA3195515A patent/CA3195515A1/en active Pending
- 2021-09-29 WO PCT/CN2021/121721 patent/WO2022068878A1/zh not_active Ceased
- 2021-09-29 TW TW110136259A patent/TW202214230A/zh unknown
- 2021-09-29 CN CN202180018263.3A patent/CN115175705B/zh active Active
- 2021-09-29 FI FIEP24204055.8T patent/FI4516357T3/fi active
- 2021-09-29 AU AU2021354823A patent/AU2021354823A1/en active Pending
- 2021-09-29 IL IL301793A patent/IL301793A/en unknown
- 2021-09-29 EP EP24204055.8A patent/EP4516357B1/en active Active
-
2022
- 2022-05-26 US US17/825,090 patent/US11685742B2/en active Active
- 2022-05-31 US US17/828,433 patent/US11607459B1/en active Active
- 2022-12-28 US US18/147,070 patent/US11952384B2/en active Active
-
2023
- 2023-03-22 US US18/187,935 patent/US12434077B2/en active Active
- 2023-10-26 US US18/495,455 patent/US12091418B2/en active Active
- 2023-11-10 US US18/506,610 patent/US12168667B2/en active Active
-
2025
- 2025-08-04 US US19/289,628 patent/US20250367316A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022068878A5 (https=) | ||
| JP7551056B2 (ja) | プログラマブルなポリマー薬物 | |
| CA2945034C (en) | Macrocycles with chelating moieties for diagnostic and therapeutic use | |
| Drewry et al. | Solid-phase synthesis of trisubstituted guanidines | |
| AU2010336403B2 (en) | Radiopharmaceutical complexes | |
| WO2019071153A1 (en) | PROGRAMMABLE DENDRITIC MEDICINES | |
| WO2019099789A1 (en) | Programmable polymeric drugs | |
| AU2022252848B2 (en) | Macrocyclic ligands with pendant chelating moieties and complexes thereof | |
| CA2660658A1 (en) | Osmium compounds | |
| NL2020121B1 (en) | Platinum-based functional moieties for preparing cell targeting conjugates | |
| RU2762891C2 (ru) | Способы получения цитотоксических производных бензодиазепина | |
| WO2019173639A1 (en) | Macrocyclic ligands with pendant chelating moieties and complexes thereof | |
| AU2013344514B2 (en) | Di-Macrocycles | |
| CA2130853A1 (en) | Process for the syntheses of monosulphonated phthalocyanines, naphthobenzoporphyrazines and porphyrins via a modified meerwein reaction | |
| CN105440059B (zh) | 氨基酸与邻菲啰啉或其衍生物的铜配合物及其制备方法和应用 | |
| CA2062483A1 (en) | Chelates, their metal complexes as well as their use in diagnosis and treatment | |
| JP2006520360A (ja) | シクロブタン−１，１−ジカルボキシレートリガンドを有する白金錯体の蛋白結合誘導体 | |
| CN104672213A (zh) | 一种具有抗肿瘤活性的酰胺类化合物及其应用 | |
| JPH02215786A (ja) | アシル化法 | |
| JP6853958B2 (ja) | ペンタフルオロスルファニルピリジル基含有ジアリールヨードニウム塩 | |
| KR20250168470A (ko) | 캄프토테신 유도체의 항체-약물 접합체 및 이의 용도 | |
| CN121574141A (zh) | 一种环金属型有机金（iii）配合物及其制备方法 | |
| ES2452719B1 (es) | Compuestos antitumorales de rutenio (II) | |
| EP4629983A1 (en) | Process for making antibody-drug conjugates | |
| JPH1180140A (ja) | ベンゾオキサゾリウム誘導体の製造方法 |